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Clinical PerspectiveWhat Is New?Type 2 diabetes mellitus is associated with smaller left ventricular volumes and higher mitral E/e′ ratio in patients with heart failure.Type 2 diabetes mellitus impacts negatively on quality of life and cardiovascular outcomes in patients with heart failure.Distinct differences are noted between heart failure phenotypes.What Are the Clinical Implications?Primary prevention and treatment interventions are needed to tackle this twin scourge of disease.

Introduction {#jah34313-sec-0009}
============

The prevalence of diabetes mellitus has increased worldwide during the past 3 decades, with the largest projected increases occurring in Asia.[1](#jah34313-bib-0001){ref-type="ref"} Diabetes mellitus increases the risk of developing heart failure (HF), and patients with both conditions are known to have particularly poor outcomes.[2](#jah34313-bib-0002){ref-type="ref"}

Most previous studies of diabetes mellitus and HF have focused on Western populations, and data on the relationship between diabetes mellitus and HF phenotypes in Asia are lacking.[2](#jah34313-bib-0002){ref-type="ref"} Knowledge gleaned from Western cohorts may not be readily extrapolated to Asians, particularly in light of recent studies showing distinct differences between Asians and white populations.[3](#jah34313-bib-0003){ref-type="ref"}, [4](#jah34313-bib-0004){ref-type="ref"}

The effect of diabetes mellitus on cardiac remodeling is uncertain, with studies showing potential development of either dilated or restrictive left ventricular (LV) phenotypes with diabetes mellitus.[5](#jah34313-bib-0005){ref-type="ref"} Data on how LV remodeling patterns with diabetes mellitus differ between patients with HF with reduced ejection fraction (HFrEF) versus those with preserved ejection fraction (HFpEF) are scarce. We are not aware of any prior study having concurrent comparative echocardiographic findings in normal controls, patients with HFpEF, and patients with HFrEF with and without diabetes mellitus.

Using data from the multinational ASIAN‐HF (Asian Sudden Cardiac Death in Heart Failure) Registry and community‐based controls without HF, we aim to examine the association between type 2 diabetes mellitus and the key domains of cardiac remodeling, quality of life (QoL), and clinical outcomes, in patients with both HFpEF and HFrEF. In addition, we aim to study the interactions between diabetes mellitus and HF phenotype on these domains.

Methods {#jah34313-sec-0010}
=======

The study data and materials used to conduct the research cannot be made available to other researchers, for purposes of reproducing the results or replicating the procedure, because of the legal restrictions imposed by multinational jurisdictions.

Study Population {#jah34313-sec-0011}
----------------

Details of the ASIAN‐HF Registry have been published in detail.[6](#jah34313-bib-0006){ref-type="ref"} In brief, the ASIAN‐HF Registry is a prospective, observational, multinational registry of Asian patients, aged \>18 years, with symptomatic HF (at least one documented episode of decompensated HF in the previous 6 months that resulted in a hospital admission or equivalent treatment). Eligible patients were enrolled from 46 medical centers across 11 Asian regions using uniform protocols and standardized procedures, with all data captured in an electronic database. Data collection included demographic variables, clinical symptoms, functional status, QoL scores, cardiovascular history, and clinical risk factors. Patients in the ASIAN‐HF Registry were recruited in 2 stages: those with HFrEF were enrolled between October 2012 and December 2015, overlapping with recruitment of those with HFpEF, between September 2013 and October 2016. Recruitment of patients with HFpEF started later than the recruitment of patients with HFrEF, for funding reasons. However, the delay was only 1 year. Hence, we do not anticipate substantial shifts in epidemiological features or treatment of patients with HFrEF or HFpEF during this year to bias regional patterns of multimorbidity, although this cannot be entirely excluded.

Type 2 diabetes mellitus was defined as the presence of the clinical diagnosis (fasting plasma glucose ≥7 mmol/L, random plasma glucose ≥11.1 mmol/L, or glycated hemoglobin ≥6.5%) or a self‐reported history of diabetes mellitus and/or receiving antidiabetic therapy at baseline. Transthoracic echocardiography and 12‐lead electrocardiography were performed by protocol at baseline. Patients with HFrEF were defined as those with EF \<40%, whereas patients with HFpEF were defined as those with an EF ≥50% on baseline echocardiography. In addition to history of HF decompensation within 6 months and presence of typical symptoms and signs of HF, 99.5% of patients with HFpEF had echocardiographic evidence for diastolic dysfunction (E/e′ ≥13, E′ medial/lateral \<9 ms, left atrial (LA) enlargement, or LV hypertrophy \[LVH\]).[7](#jah34313-bib-0007){ref-type="ref"} Patients were followed up for the outcomes of death and hospitalization, which were independently adjudicated by a clinical end point committee using prespecified criteria.[6](#jah34313-bib-0006){ref-type="ref"}

Community‐based controls without HF (n=965, 84 with diabetes mellitus) were recruited as part of the control arm of the SHOP (Singapore Heart Failure Outcomes and Phenotypes) study.[8](#jah34313-bib-0008){ref-type="ref"} Controls were free‐living adults without HF, identified from the general community of Singapore, using random sampling by door‐to‐door census of all residents in 5 designated precincts of Singapore. Controls underwent a detailed clinical examination as well as echocardiography. Both patients and controls provided informed consent, and ethics approvals were obtained from the local Institutional Review Board of each participating center.

Echocardiography {#jah34313-sec-0012}
----------------

The echocardiography protocol has been published.[6](#jah34313-bib-0006){ref-type="ref"} Briefly, echocardiography was performed at each center according to international guidelines, with a core laboratory providing detailed imaging protocols, training, oversight, and quality assurance, ensuring the accuracy and reproducibility of results.[6](#jah34313-bib-0006){ref-type="ref"} Echocardiographic parameters captured included LV dimensions and volume, LVEF, wall thickness, LA volumes, and LV mass. These were indexed to body surface area and measured according to published guidelines.[9](#jah34313-bib-0009){ref-type="ref"} Relative wall thickness (RWT) was calculated as follows: (2×diastolic posterior wall thickness)/diastolic LV internal diameter. LVH was defined as indexed LV mass index \>115 g/m^2^ in men and \>95 g/m^2^ in women.[9](#jah34313-bib-0009){ref-type="ref"} Normal cardiac geometry was defined as having no LVH and an RWT ≤0.42. Abnormal LV geometry was categorized as concentric remodeling (no LVH and RWT \>0.42), eccentric hypertrophy (LVH and RWT ≤0.42), and concentric hypertrophy (LVH and RWT \>0.42), as per guidelines.[9](#jah34313-bib-0009){ref-type="ref"}

Health‐Related QoL {#jah34313-sec-0013}
------------------

The Kansas City Cardiomyopathy Questionnaire (KCCQ) was used to assess the health‐related QoL. The KCCQ is a 23‐item, self‐administered questionnaire assessing the domains of physical function, symptoms, social function, self‐efficacy and knowledge, and QoL; it is validated in multiple HF‐related disease states and in several languages.[10](#jah34313-bib-0010){ref-type="ref"} An overall summary score can be derived from each domain, with scores ranging from 0 to 100 (higher scores indicate better health status).[10](#jah34313-bib-0010){ref-type="ref"} Non--English‐speaking participants used certified versions of the KCCQ translated into their native languages.[10](#jah34313-bib-0010){ref-type="ref"}

Outcomes {#jah34313-sec-0014}
--------

The principal outcomes evaluated were all‐cause mortality and the composite of all‐cause mortality or HF hospitalization, each at 1 year. Secondary outcomes included cardiovascular mortality and HF hospitalization at 1 year. Causes of cardiovascular death were further subclassified as attributable to sudden cardiac death (SCD), HF, acute myocardial infarction, stroke, other or presumed cardiovascular death.

Statistical Analyses {#jah34313-sec-0015}
--------------------

Analyses were performed separately in patients with HFrEF and HFpEF. Descriptive statistics were used to present baseline characteristics in patients with and without diabetes mellitus and included means and SDs, numbers and percentages, or medians and interquartile ranges. Correspondingly, differences between patients with and without diabetes mellitus were compared by Student *t* test, χ^2^ test, or Wilcoxon rank sum test, as appropriate. Multivariable logistic regression was performed to identify independent demographic and clinical associates of diabetes mellitus, including variables significant on univariable analysis and a priori selection of variables based on clinical significance. These variables included the following: age, sex, ethnicity, regional income, heart rate, body mass index (BMI), chronic kidney disease, hypertension, history of coronary artery disease, atrial fibrillation, prior stroke, and peripheral arterial disease. KCCQ scores were similarly adjusted for demographic factors, clinical variables, and medications and presented as adjusted (marginal) means and associated SEMs. Cox proportional hazards models were used to assess the association of diabetes mellitus with clinical outcomes and further adjusted for confounders in the overall group. No violation of the proportionality hazards assumption for Cox models was observed with the use of statistical tests and graphical diagnostics (based on the Schoenfeld residuals). Competing risks of death were accounted for in the analysis of HF hospitalizations. The time to outcome in Cox regression was defined as the time from baseline visit to the event of interest (eg, death or hospitalization for HF) and censored at the last visit or 1 year, whichever was earlier. Cox models were adjusted for age, sex, ethnicity, regional income, enrollment type, HF group, systolic blood pressure, heart rate, BMI, history of coronary artery disease, atrial fibrillation, peripheral arterial disease, chronic kidney disease, retinopathy, neuropathy, obstructive pulmonary disease, and use of HF medications.

The associations of QoL, echocardiographic features, and outcomes with diabetes mellitus were tested for interactions to assess if these relationships differed between HFrEF and HFpEF. Interaction analyses were also performed between diabetes mellitus and the following: (1) ethnicity as a factor variable, (2) BMI as a continuous variable, and (3) national income level as a factor variable for the respective outcomes, where national income level was as defined by the World Health Organization (lower: Indonesia, Philippines, and India; middle: China, Thailand, and Malaysia; higher: Singapore, Hong Kong, Taiwan, South Korea, and Japan). Stratified analyses were performed if interactions were significant. All statistical analyses were performed using Stata, version 14.0 (StataCorp). *P*≤0.05 was considered statistically significant; all tests were performed 2 sided.

Results {#jah34313-sec-0016}
=======

Prevalence of Diabetes Mellitus {#jah34313-sec-0017}
-------------------------------

Of a total of 6167 patients in the ASIAN‐HF Registry, 5028 had HFrEF (mean age, 60.0±13.1 years; 78.2% men; LVEF, 27.3±7.1%) and 1139 had HFpEF (mean age, 68.7±12.3 years; 50.3% men; LVEF, 61.0±7.2%). The prevalence of type 2 diabetes mellitus was higher in those with HFpEF (45.0%) compared with those with HFrEF (40.2%) (*P*=0.003), and the average duration of diabetes mellitus was longer in those with HFpEF (12.0±8.3 years) compared with those with HFrEF (9.8±8.2 years) (*P*\<0.001). In both HFrEF and HFpEF, patients with diabetes mellitus were more likely to be from Southeast Asia and the high‐income regions (Table [1](#jah34313-tbl-0001){ref-type="table"}). Prevalence of type 2 diabetes mellitus was lowest in China (at 22.8%) and highest in Singapore (at 58.2%) and Hong Kong (at 56.9%). Among 965 community‐based controls without HF (mean age, 57.3±10.3 years; 48.7% men), 8.7% (n=84) had diabetes mellitus.

###### 

Baseline Characteristics of the Study Population

  Characteristics                                           HFrEF          HFpEF                                                                                                                                                         
  --------------------------------------------------------- -------------- -------------------------------------------------- -------------- --------- -------------- --------------------------------------------------- -------------- ---------
  No.                                                       5028           2021                                               3007           ...       1139           513                                                 626            ...
  Duration of diabetes mellitus                             ...            9.8 (8.2)[a](#jah34313-note-0004){ref-type="fn"}   ...            ...       ...            12.0 (8.3)[b](#jah34313-note-0005){ref-type="fn"}   ...            ...
  Demographics                                                                                                                                                                                                                           
  Age, y                                                    60.0 (13.1)    61.9 (10.9)                                        58.8 (14.3)    \<0.001   68.7 (12.3)    69.4 (10.8)                                         68.1 (13.4)    0.081
  Women                                                     1095 (21.8)    425 (21.0)                                         670 (22.3)     0.290     566 (49.7)     262 (51.1)                                          304 (48.6)     0.400
  Ethnicity                                                                                                                                  \<0.001                                                                                     \<0.001
  Chinese                                                   1513 (30.1)    618 (30.6)                                         895 (29.8)               579 (50.8)     271 (52.8)                                          308 (49.2)     
  Indian                                                    1567 (31.2)    649 (32.1)                                         918 (30.5)               275 (24.1)     102 (19.9)                                          173 (27.6)     
  Malay                                                     790 (15.7)     391 (19.3)                                         399 (13.3)               124 (10.9)     89 (17.3)                                           35 (5.6)       
  Japanese                                                  523 (10.4)     161 (8.0)                                          362 (12.0)               117 (10.3)     37 (7.2)                                            80 (12.8)      
  Korean                                                    304 (6.0)      91 (4.5)                                           213 (7.1)                35 (3.1)       6 (1.2)                                             29 (4.6)       
  Thai                                                      167 (3.3)      58 (2.9)                                           109 (3.6)                4 (0.4)        4 (0.8)                                             0 (0.0)        
  Filipino                                                  46 (0.9)       13 (0.6)                                           33 (1.1)                 4 (0.4)        3 (0.5)                                             1 (0.2)        
  Indigenous                                                105 (2.1)      34 (1.7)                                           71 (2.4)                 1 (0.1)        1 (0.2)                                             0 (0.0)        
  Others                                                    13 (0.3)       6 (0.3)                                            7 (0.2)                                                                                                    
  Geographical region                                                                                                                        \<0.001                                                                                     \<0.001
  Northeast Asia                                            1605 (31.9)    511 (25.3)                                         1094 (36.4)              531 (46.6)     209 (40.7)                                          322 (51.4)     
  South Asia                                                1361 (27.1)    493 (24.4)                                         868 (28.9)               220 (19.3)     62 (12.1)                                           158 (25.2)     
  Southeast Asia                                            2062 (41.0)    1017 (50.3)                                        1045 (34.7)              388 (34.1)     242 (47.2)                                          146 (23.3)     
  Economic development                                                                                                                       \<0.001                                                                                     \<0.001
  Low income                                                1721 (34.2)    616 (30.5)                                         1105 (36.8)              239 (21.0)     72 (14.0)                                           167 (26.7)     
  Middle income                                             1155 (23.0)    424 (21.0)                                         731 (24.3)               73 (6.4)       45 (8.8)                                            28 (4.5)       
  High income                                               2152 (42.8)    981 (48.5)                                         1171 (38.9)              827 (72.6)     396 (77.2)                                          431 (68.9)     
  Clinical characteristics                                                                                                                                                                                                               
  NYHA                                                                                                                                       0.036                                                                                       0.140
  Class I                                                   588 (12.8)     242 (13.2)                                         346 (12.5)               153 (16.3)     62 (13.9)                                           91 (18.6)      
  Class II                                                  2406 (52.3)    938 (51.3)                                         1468 (53.0)              556 (59.3)     265 (59.3)                                          291 (59.4)     
  Class III                                                 1324 (28.8)    555 (30.3)                                         769 (27.7)               202 (21.6)     107 (23.9)                                          95 (19.4)      
  Class IV                                                  282 (6.1)      94 (5.1)                                           188 (6.8)                26 (2.8)       13 (2.9)                                            13 (2.6)       
  Shortness of breath on exertion                           3770 (75.0)    1485 (73.6)                                        2285 (76.0)    0.050     683 (60.0)     334 (65.1)                                          349 (55.8)     0.001
  Shortness of breath at rest                               926 (18.4)     399 (19.8)                                         527 (17.5)     0.046     135 (11.9)     72 (14.0)                                           63 (10.1)      0.039
  Reduction in exercise tolerance                           3531 (70.3)    1376 (68.2)                                        2155 (71.7)    0.008     673 (59.1)     334 (65.1)                                          339 (54.2)     \<0.001
  Nocturnal cough                                           923 (18.4)     374 (18.5)                                         549 (18.3)     0.820     148 (13.0)     77 (15.0)                                           71 (11.3)      0.067
  Orthopnea                                                 1135 (22.6)    492 (24.4)                                         643 (21.4)     0.013     174 (15.3)     94 (18.3)                                           80 (12.8)      0.010
  Paroxysmal nocturnal dyspnea                              955 (19.0)     404 (20.0)                                         551 (18.3)     0.140     120 (10.5)     61 (11.9)                                           59 (9.4)       0.180
  Elevated jugular venous pressure                          777 (15.5)     377 (18.7)                                         400 (13.3)     \<0.001   118 (10.4)     71 (13.8)                                           47 (7.5)       \>0.001
  S3 present                                                501 (10.0)     199 (9.8)                                          302 (10.1)     0.810     23 (2.0)       10 (1.9)                                            13 (2.1)       0.880
  Peripheral edema                                          1186 (23.6)    582 (28.8)                                         604 (20.1)     \<0.001   374 (32.9)     213 (41.6)                                          161 (25.7)     \<0.001
  Pulmonary rales present                                   839 (16.7)     405 (20.0)                                         434 (14.4)     \<0.001   175 (15.4)     105 (20.5)                                          70 (11.2)      \<0.001
  Hepatomegaly                                              277 (5.5)      112 (5.5)                                          165 (5.5)      0.940     28 (2.5)       10 (1.9)                                            18 (2.9)       0.320
  Hepatojugular reflux positive                             436 (8.7)      198 (9.8)                                          238 (7.9)      0.021     71 (6.2)       43 (8.4)                                            28 (4.5)       0.007
  LV ejection fraction, %                                   27.3 (7.1)     27.4 (7.1)                                         27.2 (7.1)     0.300     61.0 (7.2)     60.9 (7.3)                                          61.1 (7.2)     0.650
  Systolic blood pressure, mm Hg                            118.3 (20.1)   120.9 (20.2)                                       116.6 (19.8)   \<0.001   132.2 (22.1)   135.2 (22.2)                                        129.8 (21.7)   \<0.001
  Diastolic blood pressure, mm Hg                           72.4 (12.6)    72.3 (12.3)                                        72.4 (12.8)    0.690     72.5 (12.9)    71.3 (12.2)                                         73.5 (13.4)    0.004
  Heart rate, bpm                                           79.6 (16.2)    80.2 (16.0)                                        79.2 (16.3)    0.029     76.1 (15.2)    76.3 (13.9)                                         76.0 (16.2)    0.770
  Body mass index, kg/m^2^                                  24.9 (5.1)     25.5 (4.9)                                         24.4 (5.2)     \<0.001   27.1 (6.0)     28.4 (6.1)                                          26.0 (5.8)     \<0.001
  BMI categories, kg/m^2^                                                                                                                    \<0.001                                                                                     \<0.001
  Underweight (\<18.5)                                      320 (6.7)      77 (4.0)                                           243 (8.5)                29 (3.2)       3 (0.7)                                             26 (5.3)       
  Normal (18.5--23)                                         1501 (31.3)    538 (27.9)                                         963 (33.6)               194 (21.3)     67 (16.1)                                           127 (25.7)     
  Overweight (23--27.5)                                     1844 (38.4)    774 (40.1)                                         1070 (37.3)              325 (35.8)     140 (33.7)                                          185 (37.4)     
  Obese (≥27.5)                                             1134 (23.6)    542 (28.1)                                         592 (20.6)               361 (39.7)     205 (49.4)                                          156 (31.6)     
  eGFR, mL/min /1.73 m^2^                                   65.9 (27.8)    60.9 (27.8)                                        69.4 (27.3)    \<0.001   61.5 (28.8)    53.9 (27.4)                                         68.6 (28.2)    \<0.001
  Comorbidities                                                                                                                                                                                                                          
  Chronic kidney disease (eGFR \[mL/min/1.73 m^2^\] \<60)   1745 (44.0)    884 (53.3)                                         861 (37.4)     \<0.001   461 (50.2)     268 (60.8)                                          193 (40.5)     \<0.001
  Ischemic cause of HF                                      2348 (46.7)    1244 (61.6)                                        1104 (36.8)    \<0.001   350 (30.9)     194 (38.0)                                          156 (25.0)     \<0.001
  Hypertension                                              2580 (51.3)    1375 (68.1)                                        1205 (40.1)    \<0.001   811 (71.2)     438 (85.4)                                          373 (59.6)     \<0.001
  Coronary artery disease                                   2498 (49.7)    1301 (64.4)                                        1197 (39.8)    \<0.001   335 (29.5)     208 (40.5)                                          127 (20.4)     \<0.001
  Atrial fibrillation                                       910 (18.1)     327 (16.2)                                         583 (19.4)     0.004     326 (28.6)     133 (25.9)                                          193 (30.8)     0.068
  Prior stroke                                              325 (6.5)      173 (8.6)                                          152 (5.1)      \<0.001   95 (8.3)       47 (9.2)                                            48 (7.7)       0.360
  Liver disease                                             168 (3.3)      64 (3.2)                                           104 (3.5)      0.570     23 (2.0)       13 (2.5)                                            10 (1.6)       0.260
  Peripheral arterial disease                               167 (3.3)      107 (5.3)                                          60 (2.0)       \<0.001   23 (2.0)       16 (3.1)                                            7 (1.1)        0.016
  Microvascular complications                                                                                                                                                                                                            
  Nephropathy                                               ...            298 (14.8)                                         ...            ...       ...            113 (22.0)                                          ...            ...
  Retinopathy                                               ...            187 (9.3)                                          ...            ...       ...            64 (12.5)                                           ...            ...
  Neuropathy                                                ...            117 (5.8)                                          ...            ...       ...            47 (9.2)                                            ...            ...
  COPD                                                      418 (8.3)      158 (7.8)                                          260 (8.7)      0.290     104 (9.1)      50 (9.7)                                            54 (8.6)       0.510
  Smoking, ever                                             2267 (45.1)    942 (46.6)                                         1325 (44.1)    0.077     259 (22.8)     120 (23.4)                                          139 (22.2)     0.620
  Alcohol, ever                                             1467 (29.2)    564 (27.9)                                         903 (30.0)     0.100     170 (15.0)     81 (15.9)                                           89 (14.2)      0.440
  Medications                                                                                                                                                                                                                            
  ACEI or ARB                                               3705 (75.2)    1439 (72.3)                                        2266 (77.2)    \<0.001   669 (66.8)     327 (69.1)                                          342 (64.7)     0.130
  β Blockers                                                3798 (77.1)    1542 (77.5)                                        2256 (76.9)    0.610     676 (67.5)     326 (68.9)                                          350 (66.2)     0.350
  Diuretics                                                 4038 (82.0)    1693 (85.1)                                        2345 (79.9)    \<0.001   709 (70.8)     356 (75.3)                                          353 (66.7)     0.003
  MRA                                                       2878 (58.4)    1079 (54.2)                                        1799 (61.3)    \<0.001   214 (21.4)     76 (16.1)                                           138 (26.1)     \<0.001
  Antidiabetic medications                                  ...            1307 (66.5)                                        ...            ...       ...            335 (68.4)                                          ...            ...
  Metformin                                                 ...            692 (35.2)                                         ...            ...       ...            154 (31.4)                                          ...            ...
  Sulfonylureas                                             ...            705 (35.9)                                         ...            ...       ...            170 (34.7)                                          ...            ...
  Gliptins                                                  ...            227 (11.6)                                         ...            ...       ...            76 (15.5)                                           ...            ...
  α‐Glucosidase inhibitors                                  ...            134 (6.8)                                          ...            ...       ...            24 (4.9)                                            ...            ...
  Meglitinides                                              ...            24 (1.2)                                           ...            ...       ...            8 (1.6)                                             ...            ...
  Insulins                                                  ...            327 (16.6)                                         ...            ...       ...            103 (21.0)                                          ...            ...

Data are given as number (percentage) or mean (SD). ACEI indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; bpm, beats per minute; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.

Duration of diabetes mellitus reported in n=1339 patients with HFrEF.

Duration of diabetes mellitus reported in n=344 patients with HFpEF.

Baseline Correlates of Diabetes Mellitus {#jah34313-sec-0018}
----------------------------------------

In HFrEF, but not HFpEF (Table [1](#jah34313-tbl-0001){ref-type="table"}), patients with diabetes mellitus were older than those without diabetes mellitus. In both HFpEF and HFrEF, patients with diabetes mellitus had a higher prevalence of overweight/obesity than those without diabetes mellitus. Obesity was more prevalent in those with HFpEF and diabetes mellitus than in those with HFrEF and diabetes mellitus (49.4% versus 28.1%; *P*\<0.001). Of note, 31.9% of patients with HFrEF (versus 16.8% of patients with HFpEF) with diabetes mellitus were either normal weight or underweight. In both HFrEF and HFpEF, patients with diabetes mellitus also had a higher prevalence of chronic kidney disease, hypertension, coronary artery disease, and peripheral arterial disease, and were more likely to present with signs and symptoms of HF, compared with those without diabetes mellitus. Yet, compared with patients without diabetes mellitus, those with diabetes mellitus were less likely to be prescribed a mineralocorticoid receptor antagonist (in HFrEF and HFpEF) and an angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker (in HFrEF), but more likely to be given diuretics and as likely to be prescribed β‐blockers (in HFrEF and HFpEF). For anti--diabetes mellitus therapy, the most commonly used medications in both HFrEF and HFpEF were metformin, a sulfonylurea, insulin, and a dipeptidyl peptidase‐4 inhibitor. Table [2](#jah34313-tbl-0002){ref-type="table"} shows the variables independently correlated with diabetes mellitus in HFrEF and HFpEF. In HFrEF, positive correlates included the following: older age, Indian or Malay ethnicity, dwelling in a middle‐/high‐income region, higher BMI, presence of chronic kidney disease, hypertension, coronary artery disease, peripheral arterial disease, and prior stroke. In contrast, patients of Japanese or Korean descent (versus Chinese) and those with atrial fibrillation were negatively associated with diabetes mellitus in HFrEF. Independent correlates of diabetes mellitus in HFpEF included the following: Indian or Malay ethnicity, dwelling in a high‐income region, higher BMI, and presence of chronic kidney disease, hypertension, or coronary artery disease.

###### 

Clinical Correlates of Diabetes Mellitus

  Variable                      HFrEF                  HFpEF                            
  ----------------------------- ---------------------- --------- ---------------------- ---------
  Age, y                        1.011 (1.004--1.017)   0.002     0.999 (0.984--1.016)   0.745
  Women                         1.10 (0.92--1.32)      0.297     0.99 (0.71--1.39)      0.953
  Ethnicity                                                                             
  Chinese                       1.00 (Reference)       ···       1.00 (Reference)       ···
  Indian                        2.86 (2.13--3.84)      \<0.001   1.98 (0.96--4.13)      0.066
  Malay                         1.96 (1.54--2.51)      \<0.001   2.53 (1.39--4.60)      0.002
  Japanese/Korean               0.66 (0.53--0.82)      \<0.001   0.64 (0.39--1.05)      0.076
  Economic development                                                                  
  Low income                    1.00 (Reference)       ···       1.00 (Reference)       ···
  Middle income                 1.64 (1.22--2.21)      0.001     1.66 (0.52--5.32)      0.393
  High income                   3.01 (2.28--3.97)      \<0.001   3.06 (1.39--6.73)      0.005
  Heart rate, bpm               1.008 (1.003--1.013)   0.001     0.999 (0.988--1.011)   0.928
  Body mass index, kg/m^2^      1.042 (1.027--1.058)   \<0.001   1.051 (1.020--1.083)   0.001
  Chronic kidney disease        1.48 (1.27--1.72)      \<0.001   1.86 (1.32--2.61)      \<0.001
  Hypertension                  2.32 (2.00--2.69)      \<0.001   2.64 (1.72--4.06)      \<0.001
  Coronary artery disease       2.21 (1.89--2.57)      \<0.001   1.92 (1.33--2.76)      0.001
  Atrial fibrillation           0.78 (0.65--0.95)      0.012     0.76 (0.53--1.10)      0.149
  Prior stroke                  1.34 (1.01--1.76)      0.039     0.66 (0.37--1.19)      0.167
  Peripheral arterial disease   1.87 (1.27--2.76)      0.002     2.88 (0.71--11.7)      0.139

Bpm indicates beats per minute; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.

Adjusted for age, sex, ethnicity, regional income, heart rate, body mass index, chronic kidney disease, hypertension, history of coronary artery disease, atrial fibrillation, prior stroke, and peripheral arterial disease.

Diabetes Mellitus and Cardiac Remodeling {#jah34313-sec-0019}
----------------------------------------

Among controls without HF, diabetes mellitus was associated with thicker LV walls, smaller indexed LV end‐diastolic and end‐systolic volumes, higher E/e′ ratio, and greater prevalence of abnormal LV geometry (concentric LV remodeling, concentric hypertrophy, and eccentric hypertrophy), compared with those without diabetes mellitus (Table [3](#jah34313-tbl-0003){ref-type="table"}).

###### 

Echocardiographic Findings by Diabetic Status

  Variable                            HFrEF               HFpEF               Controls                                                                                             
  ----------------------------------- ------------------- ------------------- ---------- ------------------- ------------------- --------- ------------------- ------------------- ---------
  Echocardiographic characteristics                                                                                                                                                
  LV ED dimension, mm                 60 (55--66)         62 (56--69)         \<0.001    47 (43--52)         47 (44--53)         0.230     47 (45--49)         47 (44--50)         0.860
  LV ES dimension, mm                 51 (45--57)         53 (46--60)         \<0.001    30 (27--34)         30 (27--34)         0.520     28 (26--30)         28 (25--31)         0.550
  Indexed LV ED volume, mL/m^2^       91 (73--114)        103 (82--129)       \<0.001    50 (39--65)         55 (43--72)         0.003     48 (43--58)         54 (45--64)         \<0.001
  Indexed LV ES volume, mL/m^2^       65 (49--84)         74 (55--98)         \<0.001    21 (16--31)         23 (16--33)         0.130     17 (15--22)         20 (16--24)         0.014
  LV ejection fraction                28 (22--33)         28 (22--33)         0.340      60 (55--65)         60 (55--65)         0.650     63 (61--66)         64 (61--67)         0.880
  E/e′ ratio                          20.4 (15.0--28.0)   17.0 (12.7--24.5)   \<0.001    16.7 (13.1--21.8)   14.3 (10.9--18.2)   \<0.001   11.0 (9.2--12.9)    9.2 (7.7--11.2)     \<0.001
  IVSD, mm                            9.0 (8.0--11.0)     9.0 (8.0--10.0)     \<0.001    11.0 (9.5--12.0)    10.0 (9.0--12.0)    \<0.001   10.0 (8.5--11.0)    9.0 (8.0--10.0)     \<0.001
  PWTD, mm                            9.0 (8.0--10.8)     9.0 (8.0--10.0)     0.230      11.0 (9.0--12.0)    10.0 (9.0--12.0)    0.003     9.0 (8.0--10.0)     8.0 (7.0--9.0)      \<0.001
  Indexed LV mass, g/m^2^             128 (104--155)      135 (110--170)      \<0.001    102 (83--128)       102 (85--130)       0.520     84 (76--99)         79 (67--93)         0.001
  Relative wall thickness             0.31 (0.26--0.37)   0.30 (0.25--0.35)   \<0.001    0.44 (0.38--0.53)   0.43 (0.36--0.50)   \<0.001   0.40 (0.34--0.43)   0.36 (0.31--0.41)   \<0.001
  Indexed LAV, mL/m^2^                39 (27--51)         37 (23--53)         0.032      31 (21--44)         39 (27--54)         \<0.001   26 (22--31)         27 (23--30)         0.750
  LVH, n (%)                          1014 (66.4)         1716 (73.5)         \<0.001    154 (46.4)          168 (47.7)          0.730     20 (24.1)           93 (10.6)           \<0.001
  Increased RWT (\>0.42), n (%)       217 (13.7)          232 (9.6)           \<0.001    250 (60.1)          230 (51.1)          0.008     28 (33.3)           171 (19.5)          0.003
  LV geometry, n (%)                                                                                                             0.034                                             \<0.001
  No remodeling                       455 (29.8)          562 (24.1)          \<0.001    88 (26.5)           103 (29.3)                    46 (55.4)           647 (73.7)          
  Concentric remodeling               57 (3.7)            58 (2.5)                       90 (27.1)           81 (23.0)                     17 (20.5)           138 (15.7)          
  Concentric hypertrophy              153 (10.0)          163 (7.0)                      103 (31.0)          88 (25.0)                     10 (12.0)           33 (3.8)            
  Eccentric hypertrophy               861 (56.4)          1553 (66.5)                    51 (15.4)           80 (22.7)                     10 (12.0)           60 (6.8)            

Data are given as median (interquartile range) for continuous variables. ED indicates end diastolic; ES, end systolic; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IVSD, interventricular septal thickness in diastole; LAV, left atrial volume; LV, left ventricular; LVH, LV hypertrophy; PWTD, posterior wall thickness in diastole; RWT, relative wall thickness.

Among patients with HFrEF, diabetes mellitus (versus no diabetes mellitus) was associated with smaller indexed LV end‐diastolic and end‐systolic volumes, a higher E/e′ ratio, but similar LV wall thickness. These associations persisted after correcting for age, sex, ethnicity, and hypertension (*P*\<0.001 for indexed LV end‐diastolic and end‐systolic volumes and E/e′ ratio; *P*=0.434 for LV wall thickness). The most common LV geometry present in patients with HFrEF was eccentric hypertrophy. There were no significant interactions between income level (*P*=0.526), ethnicity (*P*=0.580), or BMI (*P*=0.195) with diabetes mellitus on its association with LV geometry.

Among patients with HFpEF, diabetes mellitus (versus no diabetes mellitus) was also associated with a thicker LV wall, smaller indexed LV end‐diastolic volumes, and higher mitral E/e′ ratio but smaller indexed LA volumes. These associations persisted after adjusting for the confounders above (*P*=0.037, *P*=0.017, *P*=0.029, and *P*=0.002 for LV wall thickness, indexed LV end‐diastolic volumes, E/e′ ratio, and indexed LA volume, respectively). The predominant geometry was concentric hypertrophy. There were no significant interactions between income level (*P*=0.567), ethnicity (*P*=0.763), or BMI (*P*=0.197) with diabetes mellitus on its association with LV geometry (Table [3](#jah34313-tbl-0003){ref-type="table"} and Figure [1](#jah34313-fig-0001){ref-type="fig"}.

![Left ventricular geometry by heart failure (HF) type and type 2 diabetes mellitus (T2DM). HFpEF indicates HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction.](JAH3-8-e013114-g001){#jah34313-fig-0001}

Diabetes Mellitus and Health‐Related QoL {#jah34313-sec-0020}
----------------------------------------

Compared with those without diabetes mellitus, patients with diabetes mellitus in both HF phenotypic groups had worse QoL (lower physical limitation score, symptom burden and total symptom score, social limitation, and clinical summary and overall summary KCCQ scores) (Table [4](#jah34313-tbl-0004){ref-type="table"}). There were significant interactions between diabetes mellitus and HF phenotype for physical limitation score (*P* ~interaction~=0.002), QoL score (*P* ~interaction~=0.001), social limitation (*P* ~interaction~=0.001), clinical summary score (*P* ~interaction~=0.006), and overall summary score (*P* ~interaction~=0.001), indicating that the extent to which diabetes mellitus affected these QoL domains differed by HF phenotype. For the clinical and overall summary scores, scores were lower in those with diabetes mellitus (compared with those without diabetes mellitus) in both HFrEF and HFpEF, with more prominent differences in HFpEF.

###### 

KCCQ Scores by Diabetic Status

  Quality‐of‐Life Domains     *P* ~interaction~ (Diabetes Mellitus×HF Group)   HFrEF        HFpEF                                          
  --------------------------- ------------------------------------------------ ------------ ------------ ------- ------------ ------------ ---------
  Physical limitation score   0.002                                            66.5 (0.6)   68.8 (0.5)   0.007   70.6 (1.2)   77.8 (1.1)   \<0.001
  Symptom stability score     0.048                                            63.1 (0.7)   63.6 (0.6)   0.597   56.4 (1.4)   59.3 (1.3)   0.139
  Symptom frequency score     0.141                                            66.6 (0.7)   69.4 (0.5)   0.001   68.0 (1.5)   73.0 (1.3)   0.014
  Symptom burden score        0.054                                            70.1 (0.6)   72.2 (0.5)   0.015   75.1 (1.2)   80.0 (1.1)   0.004
  Total symptom score         0.081                                            68.3 (0.6)   70.8 (0.5)   0.003   71.6 (1.3)   76.5 (1.1)   0.005
  Self‐efficacy score         0.050                                            64.3 (0.7)   64.8 (0.5)   0.584   65.4 (1.4)   68.4 (1.3)   0.124
  Quality‐of‐life score       0.001                                            55.8 (0.6)   56.7 (0.5)   0.259   64.4 (1.2)   69.8 (1.1)   0.001
  Social limitation score     0.001                                            59.8 (0.8)   63.1 (0.7)   0.003   70.2 (1.6)   79.5 (1.5)   \<0.001
  Overall summary score       0.001                                            62.8 (0.6)   65.0 (0.4)   0.004   69.1 (1.1)   75.8 (1.0)   \<0.001
  Clinical summary score      0.006                                            67.5 (0.6)   69.9 (0.4)   0.001   70.9 (1.1)   77.0 (1.0)   \<0.001

Data are presented as adjusted mean (SE). Adjusted for age, sex, ethnicity, regional income, hypertension, systolic blood pressure, heart rate, ejection fraction, obstructive pulmonary disease, atrial fibrillation, peripheral arterial disease, coronary artery disease, educational status, angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers, β blockers, and diuretics. HF indicates heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; KCCQ, Kansas City Cardiomyopathy Questionnaire.

Diabetes Mellitus and Clinical Outcomes {#jah34313-sec-0021}
---------------------------------------

Of 6167 patients, 5584 (90.5%) had outcome data available, whereas 583 (9.5%) were lost to follow‐up. Compared with patients without diabetes mellitus, those with type 2 diabetes mellitus had a higher 1‐year composite of all‐cause mortality/HF hospitalizations (hazard ratio \[HR\], 1.63; 95% CI, 1.45--1.84; *P*\<0.001; and adjusted HR, 1.22; 95% CI, 1.05--1.41; *P*=0.011) on univariable and multivariable analysis, respectively. There was higher 1‐year overall mortality (HR, 1.37; 95% CI, 1.16--1.62; *P*\<0.001), but this association was attenuated in multivariable analysis (adjusted HR, 1.08; 95% CI, 0.87--1.35; *P*=0.473). For secondary outcomes, the findings for cardiovascular mortality were similar to the above results on overall mortality. However, patients with diabetes mellitus (versus no diabetes mellitus) had a higher risk of HF rehospitalization at 1 year (adjusted HR, 1.27; 95% CI, 1.05--1.54; *P*=0.014). HF phenotype did not modify these relationships (*P* ~interaction~\>0.05). SCD and HF death were the most common modes of cardiovascular death among those with diabetes mellitus (26.3% for SCD death, and 20.1% for HF death), as well as those without diabetes mellitus (30.6% SCD death, and 26.0% for HF death), with no difference between phenotypes (*P* ~interaction~\>0.05) (Table [5](#jah34313-tbl-0005){ref-type="table"} and Figure [2](#jah34313-fig-0002){ref-type="fig"}.

###### 

Clinical Outcomes

  1‐y Outcomes                              No. (%) of Events   Crude Hazard Ratio (95% CI)   *P* Value           *P* ~interaction~ (DM×HF Group)   Adjusted Hazard Ratio (95% CI)[a](#jah34313-note-0011){ref-type="fn"}   *P* Value           
  ----------------------------------------- ------------------- ----------------------------- ------------------- --------------------------------- ----------------------------------------------------------------------- ------------------- -------
  All‐cause mortality                       262 (11.3)          274 (8.4)                     1.37 (1.16--1.62)   \<0.001                           0.271                                                                   1.08 (0.87--1.35)   0.473
  HFrEF                                     235/1849            242/2680                      ...                 ...                               ...                                                                                         
  HFpEF                                     27/473              32/582                        ...                 ...                               ...                                                                                         
  Cardiovascular mortality                  222 (9.6)           233 (7.1)                     1.36 (1.13--1.64)   0.001                             0.326                                                                   1.07 (0.83--1.36)   0.603
  HFrEF                                     203/1849            210/2680                      ...                 ...                               ...                                                                                         
  HFpEF                                     19/473              23/582                        ...                 ...                               ...                                                                                         
  All‐cause mortality/HF hospitalizations   561 (24.2)          511 (15.7)                    1.63 (1.45--1.84)   \<0.001                           0.525                                                                   1.22 (1.05--1.41)   0.011
  HFrEF                                     491/1849            451/2680                      ...                 ...                               ...                                                                                         
  HFpEF                                     70/473              60/582                        ...                 ...                               ...                                                                                         
  HF hospitalizations                       356 (15.3)          292 (9.0)                     1.79 (1.53--2.09)   \<0.001                           0.648                                                                   1.27 (1.05--1.54)   0.014
  HFrEF                                     306/1849            260/2680                      ...                 ...                               ...                                                                                         
  HFpEF                                     50/473              32/582                        ...                 ...                               ...                                                                                         

DM indicates diabetes mellitus; HF, heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction.

DM, adjusted for age, sex, ethnicity, regional income, enrollment type, HF group, systolic blood pressure, heart rate, body mass index, history of coronary artery disease, atrial fibrillation, peripheral arterial disease, chronic kidney disease, retinopathy, neuropathy, obstructive pulmonary disease, and use of angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers, betablockers, mineralocorticoid receptor antagonists, and diuretics.

![Survival by type 2 diabetes mellitus (DM) status for various outcomes at 1 year. HF indicates heart failure; HR, hazard ratio.](JAH3-8-e013114-g002){#jah34313-fig-0002}

Discussion {#jah34313-sec-0022}
==========

We provide the first multinational prospective data from Asia describing the association between diabetes mellitus and key aspects of HF, including cardiac remodeling, QoL, and clinical outcomes, among patients with HFpEF and HFrEF. Our main findings were as follows: (1) The prevalence of type 2 diabetes mellitus was high among Asian patients with HF, especially those with HFpEF, with notable regional variation. Different correlates of diabetes mellitus were noted for both HFpEF and HFrEF. (2) Type 2 diabetes mellitus was associated with smaller indexed LV diastolic volumes and higher LV filling pressure (higher mitral E/e′ ratio) compared with patients without diabetes mellitus, in both HFrEF and HFpEF. However, there were differences in cardiac remodeling, with predominance of eccentric hypertrophy in HFrEF and concentric hypertrophy in HFpEF. (3) Compared with patients without diabetes mellitus, those with diabetes mellitus had worse QoL, with the difference more prominent in HFpEF than HFrEF, at least for some KCCQ domains. (4) Type 2 diabetes mellitus was associated with a higher risk of the composite outcome of all‐cause mortality or HF hospitalization at 1 year, driven mainly by a higher rate of HF hospitalization. The relationships between diabetes mellitus and outcome were similar in HFrEF and HFpEF.

Cardiac Remodeling {#jah34313-sec-0023}
------------------

Among controls without HF, diabetes mellitus was associated with greater LV wall thickness and abnormal LV cardiac remodeling. Similar findings have been described in several population‐based studies.[11](#jah34313-bib-0011){ref-type="ref"} Several explanatory mechanisms have been postulated, including the prohypertrophic effects of insulin, insulin growth factor‐1, and insulin resistance.[12](#jah34313-bib-0012){ref-type="ref"} In the initial insulin‐resistant phase of diabetes mellitus, circulating insulin levels are increased. Insulin is known to directly stimulate cardiomyocyte growth[13](#jah34313-bib-0013){ref-type="ref"} and indirectly via binding to the insulin growth factor‐1 receptor.[14](#jah34313-bib-0014){ref-type="ref"} Insulin growth factor‐1 itself is known to stimulate the growth of cardiac myocytes through induction of cardiac protein synthesis.[15](#jah34313-bib-0015){ref-type="ref"} We also found greater LV diastolic dysfunction (higher mitral E/e′ ratio) in controls with diabetes mellitus compared with those without diabetes mellitus, consistent with other non‐HF diabetic cohorts.[16](#jah34313-bib-0016){ref-type="ref"} Increased LV thickness and stiffness, resulting from lipotoxicity[17](#jah34313-bib-0017){ref-type="ref"} and myocardial deposition of collagen and advanced glycation end products,[16](#jah34313-bib-0016){ref-type="ref"} may explain this finding.

We found differences in diabetic cardiac remodeling between patients with HFrEF and HFpEF. Although there were smaller indexed LV end‐diastolic volumes and higher LV filling pressures in patients with versus without diabetes mellitus in both HF phenotypes, diabetes mellitus was associated with preserved LV wall thickness and a predominantly eccentric hypertrophy phenotype in HFrEF, in contrast to LV wall thickening and a predominantly concentric hypertrophy phenotype in HFpEF. Consistent with our findings, patients with HFrEF and diabetes mellitus (versus no diabetes mellitus) in the STICH (Surgical Treatment for Ischemic Heart Failure) trial had higher E/E′ ratios and smaller LV volumes[18](#jah34313-bib-0018){ref-type="ref"}; however, patients with HFpEF and diabetes mellitus (versus no diabetes mellitus) in the I‐PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction) trial had higher E/E′ ratios, thicker LV walls, and more LVH.[19](#jah34313-bib-0019){ref-type="ref"} Unlike our study, no prior studies have concomitantly included both HF types or controls without HF from the same population.

As recently described,[5](#jah34313-bib-0005){ref-type="ref"}, [20](#jah34313-bib-0020){ref-type="ref"} the mechanisms by which diabetes mellitus affects cardiac structure in HFrEF and HFpEF differ. In HFrEF, diabetes mellitus causes increased cardiac cell death with its attendant fibrosis. Cell death occurs as a result of several pathways, including lipotoxicity and deposition of advanced glycation end products.[5](#jah34313-bib-0005){ref-type="ref"}, [20](#jah34313-bib-0020){ref-type="ref"} Lipotoxicity may occur from the accumulation of triglycerides in the cardiac cells or the toxic effects of excess circulating fatty acids.[17](#jah34313-bib-0017){ref-type="ref"}, [20](#jah34313-bib-0020){ref-type="ref"} Advanced glycation end products foster inflammation, immune cell infiltration, and subsequent apoptosis.[21](#jah34313-bib-0021){ref-type="ref"} Intense replacement fibrosis follows cell death because of the stimulation of protein kinase C activity in fibroblasts by hyperglycemia.[20](#jah34313-bib-0020){ref-type="ref"} In HFpEF, cardiac cell hypertrophy and stiffness may occur because of hyperinsulinemia[13](#jah34313-bib-0013){ref-type="ref"}, [14](#jah34313-bib-0014){ref-type="ref"} as well as endothelial dysfunction resulting from coronary microvascular disease seen in diabetes mellitus[22](#jah34313-bib-0022){ref-type="ref"} with downstream lack of cGMP in the myocardium.[20](#jah34313-bib-0020){ref-type="ref"} This has been corroborated by histological findings from LV endomyocardial biopsies in which increased fibrosis and deposition of advanced glycation end products were found in HFrEF, whereas increased cardiomyocyte resting tension was observed in HFpEF.[23](#jah34313-bib-0023){ref-type="ref"} The cardiac autonomic neuropathy seen in diabetes mellitus, resulting from parasympathetic denervation and increased sympathetic tone with high circulating catecholamines,[24](#jah34313-bib-0024){ref-type="ref"} has also been shown to cause the increased LV wall stress, LVH, and concentric remodeling[25](#jah34313-bib-0025){ref-type="ref"} seen in HFpEF.

In all 3 groups, diabetes mellitus appears to confer relative "protection" from LV dilatation with diabetes mellitus, albeit by different mechanisms (namely, from insulin signaling and LVH in HFpEF versus cell death from lipotoxicity and its attendant fibrosis in HFrEF). This is also seen in the left atria of patients with HFpEF. The smaller LA volumes in HFpEF with diabetes mellitus are potentially caused by the similar inward remodeling of LA in the presence of diabetes mellitus as with the LV. This is consistent with the lower atrial fibrillation rates we found in patients with diabetes mellitus in our study as well as other published cohorts.[26](#jah34313-bib-0026){ref-type="ref"} In BENEFICIAL (A Double‐Blind, Placebo‐Controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium \[ALT‐711\] in Patients With Chronic Heart Failure), alagebrium (an advanced glycation end products cross‐link breaker) was associated with a trend toward LV dilatation in patients with HFrEF (albeit nonsignificant), in contrast to a reduction in LV end‐diastolic diameter in those receiving placebo, suggesting a role of AGE cross‐links in protecting against LV dilation.[27](#jah34313-bib-0027){ref-type="ref"} There was also a trend toward worse exercise tolerance in patients with HFrEF receiving alagebrium.[27](#jah34313-bib-0027){ref-type="ref"} Beyond HF, the phenomenon of negative remodeling with diabetes mellitus has also been described in other cardiovascular domains. Epidemiologically, there exist not only strong links of an inverse correlation between diabetes mellitus and abdominal aorta dilation but also slower aneurysm enlargement and fewer repairs for rupture in patients with diabetes mellitus.[28](#jah34313-bib-0028){ref-type="ref"}, [29](#jah34313-bib-0029){ref-type="ref"} This paradoxically protective effect of diabetes mellitus against aortic aneurysms, despite increased atherosclerosis, may in part be explained by AGE cross‐linking because alagebrium therapy was associated with aortic dilatation in elderly hypertensive dogs.[30](#jah34313-bib-0030){ref-type="ref"} Furthermore, in coronary atherosclerosis, the expected positive (outward) compensatory remodeling to maintain coronary blood flow in the presence of obstruction is absent in diabetes mellitus, with many studies showing a predominance of maladaptive negative (inward) remodeling.[31](#jah34313-bib-0031){ref-type="ref"}, [32](#jah34313-bib-0032){ref-type="ref"}

Health‐Related QoL {#jah34313-sec-0024}
------------------

There is increasing recognition of the importance of patient‐centered outcomes in HF. In both HFrEF and HFpEF, patients with diabetes mellitus had worse scores in most KCCQ domains, compared with those without diabetes mellitus. In a small study of 325 patients with HFpEF and HFrEF, diabetes mellitus was similarly associated with poorer QoL, as measured by the Minnesota Living With Heart Failure Questionnaire.[33](#jah34313-bib-0033){ref-type="ref"} The difference between patients with and without diabetes mellitus was more prominent across domains in HFpEF compared with HFrEF. This could be because either diabetes mellitus did not materially influence the already low QoL scores in the generally more symptomatic patients with HFrEF or diabetes with its attendant systemic inflammatory effects plays a greater role in HFpEF than HFrEF.

Clinical Outcomes {#jah34313-sec-0025}
-----------------

The attenuated association between diabetes mellitus and the risk of all‐cause mortality at 1 year is consistent with prior studies. In the EFFECT (Enhanced Feedback for Effective Cardiac Treatment) study, in which half of the cohort consisted of patients with HFrEF, diabetes mellitus predicted 1‐year mortality in univariable, but not in multivariable, analysis.[34](#jah34313-bib-0034){ref-type="ref"} Likewise, in the OPTIMIZE‐HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) Registry, in which approximately half the cohort had HFrEF, diabetes mellitus did not predict 90‐day mortality.[35](#jah34313-bib-0035){ref-type="ref"} A similar lack of effect of diabetes mellitus on in‐hospital mortality was seen in ADHERE (Acute Decompensated Heart Failure National Registry).[36](#jah34313-bib-0036){ref-type="ref"} However, diabetes mellitus was associated with significantly higher mortality in studies with longer follow‐up.[37](#jah34313-bib-0037){ref-type="ref"} The CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) study found diabetes mellitus to be a significant predictor of mortality, regardless of EF, over a median follow‐up of 38 months.[37](#jah34313-bib-0037){ref-type="ref"} In the I‐PRESERVE trial in patients with HFpEF, with a median follow‐up of 4.1 years, diabetes mellitus was associated with higher mortality.[38](#jah34313-bib-0038){ref-type="ref"} The finding that diabetes mellitus is not independently predictive of death in the present study and other short‐term studies, but is with longer‐term follow‐up, suggests that short‐term mortality in patients with HF and diabetes mellitus may be determined more by comorbidities and less by diabetes mellitus itself; however, over longer‐term follow‐up, the deleterious effects of diabetes mellitus may become more apparent. Although there was no significant correlation with short‐term mortality, we found that diabetes mellitus was significantly associated with HF hospitalizations at 1 year, regardless of HF phenotype. Likewise, in the OPTIMIZE‐HF Registry, diabetes mellitus predicted rehospitalization.[35](#jah34313-bib-0035){ref-type="ref"} In the CHARM study, diabetes mellitus predicted increased HF hospitalizations in both HFpEF and HFrEF cohorts. These increased hospitalizations result in increased morbidity and costs, lending further evidence to the deleterious effects of diabetes mellitus in this fragile HF population and the need for adequate prevention, screening, and management of diabetes mellitus.

We found that the most common causes of cardiovascular deaths in patients with HF were the same in those with or without diabetes mellitus (namely, SCD, followed by HF‐related events). This is consistent with outcomes in the I‐PRESERVE[38](#jah34313-bib-0038){ref-type="ref"} trial. Patients with HF and diabetes mellitus were not receiving optimal medical therapy for HF or diabetes mellitus. The uptake of angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers and mineralocorticoid receptor antagonists was lower in patients with diabetes mellitus than in those without, despite good safety data and proven benefits. Uptake of metformin was fairly low, despite current guidelines that recommend metformin as the first‐line agent unless contraindicated as well as good safety data of metformin in HF. Furthermore, the use of dipeptidyl peptidase‐4 inhibitors was not uncommon (\>10%), despite safety concerns of increased cardiovascular events and HF hospitalizations. ASIAN‐HF Registry enrollment occurred before the widespread availability of sodium‐glucose cotransporter‐2 inhibitors in Asia, and it would be interesting to examine more recent trends in antidiabetic therapy. We have previously shown that HF guideline‐directed medical therapies were underused in our Asian patients, emphasizing the need for a multipronged approach to increase patient/physician education and targeted public health strategies to improve access and availability to these therapies for better patient outcomes in Asia.[39](#jah34313-bib-0039){ref-type="ref"}

Limitations {#jah34313-sec-0026}
-----------

First, we acknowledge the potential for selection bias with inclusion of predominantly academic investigators. Treatments and outcomes reported may, therefore, reflect the best practice in each region. Second, the lack of uniform screening using glycated hemoglobin or oral glucose tolerance tests may have led to underdiagnosis of diabetes mellitus. Thus, we have likely underestimated the true burden of diabetes mellitus and its associated adverse outcomes in our Asian countries. Furthermore, the lack of glycemic control data (glycated hemoglobin) and proteinuria data in the registry did not allow for assessment of diabetes mellitus control as well as complete range of microvascular complications on outcomes. We did, however, include other microvascular complications, like nephropathy, retinopathy, and neuropathy. Third, this was a predominantly Asian cohort and excluded subjects with midrange ejection fraction (EF 40%--49%), which may potentially affect the generalizability of the results. Finally, the observational nature of our study precludes conclusions on causality. Despite adjustment for multiple variables, unaccounted confounders may potentially influence the results. Nevertheless, our results about the relationship between diabetes mellitus and LV remodeling may be regarded as hypothesis generating.

Conclusions {#jah34313-sec-0027}
===========

Among patients with HFrEF and HFpEF, type 2 diabetes mellitus is associated with smaller indexed LV diastolic volumes, higher LV filling pressures, poorer QoL, and worse cardiovascular outcomes, with several differences noted between HF phenotypes.
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###### 

**Appendix S1.** The ASIAN‐HF Investigators.

###### 

Click here for additional data file.

The contributions of all site investigators and clinical coordinators are acknowledged.

[^1]: A complete list of ASIAN‐HF (Asian Sudden Cardiac Death in Heart Failure) Registry Investigators can be found in Appendix S1.
